What is Cureatr?
Cureatr operates at the critical intersection of healthcare technology and patient safety, offering a robust platform designed to enhance medication management. The company's technology empowers prescribers with real-time, accurate medication lists at the point of care, thereby mitigating risks associated with therapeutic duplication, non-adherence, and substance abuse. Furthermore, Cureatr provides real-time alerts to care managers regarding patient medication adherence, ensuring timely interventions for complex medication therapies. The company's overarching vision is to create a world where individuals can safely and effectively access and utilize medications, leading to improved health outcomes and reduced hospitalizations.
How much funding has Cureatr raised?
Cureatr has raised a total of $19.2M across 3 funding rounds:
Debt
$425K
Series A
$5.8M
Series B
$13M
Debt (2011): $425K, investors not publicly disclosed
Series A (2013): $5.8M led by Partnership Fund for New York City, Cardinal Partners, JMI Services, and Milestone Venture Partners
Series B (2015): $13M supported by Cerner Capital, JMI Services, Cardinal Partners, Milestone Venture Partners, Windham Ventures, and Deerfield Investments
Key Investors in Cureatr
Partnership Fund for New York City
Partnership Fund for New York City is a nonprofit organization that mobilizes the private sector to address urban challenges and promote economic opportunity. It focuses on enhancing New York City's role as a global hub for innovation and economic growth.
Cardinal Partners
Cardinal Partners is a venture capital firm specializing in early-stage healthcare investments. They are committed to identifying and supporting innovative companies that aim to improve healthcare outcomes and deliver significant returns.
Milestone Venture Partners
Milestone Venture Partners is a venture capital firm focused on early-stage investments in digital health and applied technology. They partner with founders to build impactful companies in markets poised for significant value creation.
What's next for Cureatr?
With substantial enterprise-level backing and a recent strategic investment, Cureatr is well-positioned for accelerated growth and market expansion. The company's focus on addressing a critical $528 billion problem in medication management suggests a strategic imperative to scale its technology and clinical services. Future developments are likely to involve further integration of its CMM solutions into healthcare systems, enhancing predictive analytics for patient risk stratification, and potentially expanding its clinical pharmacist services. This capital infusion will likely fuel product development, broaden its customer base, and solidify its leadership in the medication management technology sector.
See full Cureatr company page
